Chronic kidney disease (CKD) patients have lower pulmonary function, respiratory and peripheral muscle strength values when compared to the general population, which reflects negatively in the quality of life (QoL). The aim of this study was to compare the pulmonary function, respiratory and peripheral muscle strength, and QoL between CKD patients and healthy individuals. Cross-sectional study with a consecutive sample of 39 individuals separated into three groups: nondialysisdependent CKD in stage 5 (CKD-5), HD group (CKD-HD), and healthy individuals.The tests performed were spirometry, manovacuometry, handgrip strength (HGS), and Medical Outcomes Short-Form Health Survey (SF-36). A significant difference between groups was observed in forced expiratory volume in 1 second (FEV 1 ) and its predicted value (p = 0.004 and p < 0.001, respectively), forced vital capacity (FVC), and its predicted value (p = 0.008 and p < 0.001, respectively), peak expiratory flow (PEF) and its predicted value (p = 0.004 and p < 0.001, respectively), maximal inspiratory pressure (MIP) and its predicted value (p = 0.022), maximal expiratory pressure (MEP) and its predicted value (p = 0.030 and p = 0.009, respectively) in which CKD-5 presented the worst values, followed by CKD-HD and healthy group. The CKD-5 had worse pulmonary function, respiratory muscle strength, and QoL. Moreover, CKD-HD also showed some impairment in pulmonary function and QoL when compared with healthy individuals. Even with the peripheral muscle strength preserved, its decrease is proportional to the pulmonary impairment in the evaluated CKD patients. K E Y W O R D S chronic kidney disease, hemodialysis, muscle strength, pulmonary function, quality of life 1 | INTRODUCTION Pulmonary function in chronic kidney disease (CKD) patients is a neglected subject and not well documented in the literature. It is known that fluid overload due to Patrícia de Souza Rezende and Francini Porcher Andrade contributed equally to this study.
Background: Kidney failure reduces life expectancy by one-third compared with the general population, and cardiovascular complications and poor cardiorespiratory fitness (CRF) are the main causes. We aimed to evaluate the association between severely low CRF and all-cause mortality risk in HD patients. Methods: This observational prospective cohort study followed-up patients receiving HD from August 2015 until March 2022. Cardiorespiratory fitness was evaluated through the cardiopulmonary exercise test, and the peak oxygen uptake (VO2peak) value was used to determine severely low CRF (< 15 mL∙kg−1∙min−1). Cox regression and univariate Kaplan-Meier analysis were used to evaluate the association of severely low CRF with mortality risk and survival rate. Results: Forty-eight patients were followed-up for a median of 33.0 [14.3 – 49.3] months. A total of 26 patients had severely low CRF. During the follow-up period, 11 patients (22.92%) died from all causes. From these, eight (30.8%) had severely low CRF. Even so, severely low CRF was not associated with crude death rates for patients stratified by CRF levels (p = 0.189), neither in unadjusted (HR 2.18; CI 95% 0.58−8.23) nor in adjusted (HR 1.32; CI 95% 0.31−5.59) Cox proportional hazard models. As a continuous variable, VO2peak was not associated with mortality risk (HR 1.01; CI 95% 0.84−1.21). Univariate Kaplan-Meier analysis showed that patients with severely low CRF did not have significantly worse survival rates than those with mild-moderate CRF (p = 0.186). Conclusion: Our findings indicated that severely low CRF was not associated with all-cause mortality in patients on HD. Despite severely low CRF being prevalent, larger cohort studies are needed to establish strong conclusions on its association with all-cause mortality.
RESUMO Introdução A insuficiência renal reduz a expectativa de vida em um terço comparada à população em geral. Complicações cardiovasculares e baixa aptidão cardiorrespiratória (ACR) são as principais causas. Avaliamos a associação entre ACR muito baixa e risco de mortalidade por todas as causas em pacientes em HD. Métodos Este estudo de coorte prospectivo observacional acompanhou pacientes em HD de agosto/2015 a março/2022. Avaliou-se a aptidão cardiorrespiratória pelo teste de exercício cardiopulmonar, e o valor do pico do consumo de oxigênio (VO2pico) foi usado para determinar ACR muito baixa (< 15 mL∙kg−1∙min−1). Utilizamos regressão de Cox e análise univariada de Kaplan-Meier para avaliar associação da ACR muito baixa com o risco de mortalidade e taxa de sobrevida. Resultados Acompanhamos 48 pacientes por uma média de 33,0 [14,3 – 49,3] meses. Um total de 26 pacientes apresentaram ACR muito baixa. No período de acompanhamento, 11 pacientes (22,92%) foram a óbito por todas as causas. Destes, oito (30,8%) apresentavam ACR muito baixa. Mesmo assim, ACR muito baixa não foi associada a taxas brutas de mortalidade para pacientes estratificados por níveis de ACR (p = 0,189), nem em modelos de risco proporcional de Cox não ajustados (HR 2,18; IC 95% 0,58–8,23) ou ajustados (HR 1,32; IC 95% 0,31–5,59). Como variável contínua, VO2pico não foi associado ao risco de mortalidade (HR 1,01; IC 95% 0,84–1,21). A análise univariada de Kaplan-Meier mostrou que pacientes com ACR muito baixa não apresentaram taxas de sobrevida significativamente piores do que aqueles com ACR leve-moderada (p = 0,186). Conclusão Nossos achados indicaram que a ACR muito baixa não foi associada à mortalidade por todas as causas em pacientes em HD. Apesar de ACR muito baixa ser prevalente, são necessários estudos de coorte maiores para estabelecer conclusões sólidas sobre sua associação com mortalidade por todas as causas.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.